Beyond a Single KRAS Inhibitor: China-Originated Therapeutics and the Rise of Resistance-Directed Combinations
none
3 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
none
Abstract Background: Epidermal growth factor receptor (EGFR) mutations are the most clinically actionable oncogenic drivers in Asian patients with non-small-cell lung cancer (NSCLC). The therapeutic landscape has rapidly evolved from single-agent EGFR tyrosine kinase inhibitors (TKIs) to risk-adapted first-line intensi...
Rare tumors constitute a substantial portion of cancer diagnoses, however, research remains limited. To assess the utility of genomic testing for informing treatment decisions, we retrospectively evaluated the landscape of actionable genomic alterations and immune biomarkers in rare tumors. Genomic and clinical data fr...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.